利妥昔单抗治疗Graves眼病致不良反应分析及药学监护  

Pharmaceutical Care of Adverse Reactions Caused by Rituximab in the Treatment of Graves Orbitopathy

作　　者：和心依[1] 王少科[1] 薛小荣[1] 胡斌[1] HE Xinyi;WANG Shaoke;XUE Xiaorong;HU Bin(Department of Pharmacy,Xi’an Fourth Hospital,Xi’an Shaanxi 710004,China)

机构地区：[1]西安市第四医院药剂科,陕西西安710004

出　　处：《中国药物警戒》2021年第12期1186-1188,1195,共4页Chinese Journal of Pharmacovigilance

基　　金：陕西省重点研发计划(2020SF-203)。

摘　　要：目的分析利妥昔单抗治疗Graves眼病导致不良反应的特点及其防治,为临床安全用药提供参考,为药学监护提供思路。方法对我院眼科2018年6月1日至2019年12月31日期间使用利妥昔单抗的48例患者,共计99次用药进行回顾性分析。结果48例患者中有10例发生不良反应,女性8例(80.00%),男性2例(20.00%),年龄25~54岁。累及系统-器官主要为呼吸系统,心血管系统,皮肤和皮下组织。不良反应多发于首次用药时,症状较轻微。结论对于临床使用经验及安全性研究较少新的药物治疗方案,临床药师应加强药学监护,关注患者相关生理指标及心理状态,明确药学监护重点,及时排除用药禁忌,确保用药安全,充分体现临床药师的价值。Objective To analyze the characteristics of adverse reactions caused by rituximab in the treatment of Graves orbitopathy and recommend ways of prevention and treatment so as to provide reference for clinical safe drug use and for pharmaceutical care.Methods The clinical data on a total of 48 patients who used rituximab 99 times between June 1,2018 and December 31,2019 was analyzed retrospectively.Results ADRoccurred in 10 of the 48 cases,including 8 females(80.00%)and 2 males(20.00%)aged 25 to 54.The organs/systems involved were the respiratory system,cardiovascular system,the skin and subcutaneous tissues.ADR mostly occurred the first time rituximab was administered,but the symptoms were mild.Conclusion Clinical pharmacists should strengthen pharmaceutical care when adopting treatment schemes involving new drugs that are not often used and lack safety study.Related physiological indicators and mental state of patients deserve more attention and priorities of pharmaceutical care should be specified.Contraindications should be eliminated in time to ensure medication safety and prove the worth of clinical pharmacists.

关 键 词：GRAVES眼病 利妥昔单抗 药品不良反应 药学监护 

分 类 号：R994.11[医药卫生—毒理学]